Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Period	YoY Revenue Growth
2017-08-31	283.15%
2018-08-31	-0.29%
2019-08-31	10.37%
2020-08-31	0.26%
2021-08-31	-0.26%
2022-12-31	0.00%
2023-12-31	-50.43%
2024-12-31	N/A
2025-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORMP	$3.88	+2.37%	0.15M
3
4
5

Oramed Pharmaceuticals Inc. (ORMP) Revenue Growth

Revenue Growth Data

Get Oramed Pharmaceuticals Inc. Data in Excel

More ORMP Financial Data